Novartis AG is set to present at the American Society of Hematology conference this week study data on Exjade, an FDA-approved drug designed to prevent iron accumulation in patients who have frequent blood transfusions. GlaxoSmithKline will provide results from a late-stage trial of ofatumumab, a drug candidate for chronic lymphocytic leukemia.

Full Story:

Related Summaries